- Home
- SRV vs CHRS Comparison
SRV vs CHRS Comparison
Compare SRV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- CHRS
- Stock Information
- Founded
- SRV 2007
- CHRS 2010
- Country
- SRV United States
- CHRS United States
- Employees
- SRV N/A
- CHRS N/A
- Industry
- SRV Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRV Finance
- CHRS Health Care
- Exchange
- SRV Nasdaq
- CHRS Nasdaq
- Market Cap
- SRV 193.1M
- CHRS 194.1M
- IPO Year
- SRV N/A
- CHRS 2014
- Fundamental
- Price
- SRV $43.02
- CHRS $1.73
- Analyst Decision
- SRV
- CHRS Strong Buy
- Analyst Count
- SRV 0
- CHRS 4
- Target Price
- SRV N/A
- CHRS $4.51
- AVG Volume (30 Days)
- SRV 33.9K
- CHRS 999.4K
- Earning Date
- SRV 01-01-0001
- CHRS 11-07-2025
- Dividend Yield
- SRV 13.38%
- CHRS N/A
- EPS Growth
- SRV N/A
- CHRS N/A
- EPS
- SRV N/A
- CHRS 1.55
- Revenue
- SRV N/A
- CHRS $272,209,000.00
- Revenue This Year
- SRV N/A
- CHRS N/A
- Revenue Next Year
- SRV N/A
- CHRS $109.48
- P/E Ratio
- SRV N/A
- CHRS $1.12
- Revenue Growth
- SRV N/A
- CHRS 52.33
- 52 Week Low
- SRV $30.73
- CHRS $0.66
- 52 Week High
- SRV $44.30
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- SRV 45.22
- CHRS 56.93
- Support Level
- SRV $42.00
- CHRS $1.64
- Resistance Level
- SRV $42.81
- CHRS $1.75
- Average True Range (ATR)
- SRV 0.89
- CHRS 0.10
- MACD
- SRV -0.07
- CHRS -0.02
- Stochastic Oscillator
- SRV 39.26
- CHRS 51.84
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.